logo
Your horoscope for the week ahead: Enjoy chasing comfort and glamour of all kinds as Venus moves into Taurus

Your horoscope for the week ahead: Enjoy chasing comfort and glamour of all kinds as Venus moves into Taurus

CBC2 days ago

Does it seem like time is passing too quickly? You could begin to feel that way when the emotion-ruling moon waxes into her first quarter in meticulous Virgo on Monday night or early Tuesday, depending on your time zone. This lunation often puts us on a mission to slash through our to-do list with speed and precision. Just watch that you don't lash out at others as you rush to get things done just so. The moon will go on to square chatty Mercury in impulsive Gemini, which could make us extra prickly in our interactions with one another. Remember to take a deep breath and gather your thoughts before you speak — it could protect you from saying something you'll regret.
Choosing to adopt a positive attitude could open you up to a world of possibilities on Wednesday, when relationship-ruling Venus in daring Aries sextiles lucky Jupiter in social Gemini. This affable aspect is known to ignite our collaborative sides, putting us in the mood to exchange ideas, pursue romance and simply enjoy ourselves. If you're single, this could be an excellent time to explore new dating opportunities or give someone the chance to get to know you on a deeper level. Partnered up? Take advantage of this energy to try something adventurous together and watch it revive your spark.
Then, prepare to make room for pleasures as love, beauty and money-ruling Venus enters luxury-loving Taurus on Thursday or Friday. The goddess of romance will spend the next four weeks travelling through the fixed earth sign, which is sure to bring all kinds of delightful new indulgences into our lives. Enjoy chasing comfort and glamour, but don't forget to keep an eye on your spending as well. Consider how you can draw enjoyment from what you already own and elevate your surroundings with a creative eye. Meanwhile, when it comes to matters of the heart, you may find that this transit amps up your emotions and encourages you to express your feelings through affectionate gestures and gifts. Just try not to hold on to your loved ones too tightly during this period, as possessiveness can sometimes crop up as Venus moves through Taurus.
Finally, pay attention to where your curiosity leads you when intellectual Mercury conjuncts expansive Jupiter in inquisitive Gemini on Sunday. If you can make an effort to follow your instincts and explore ideas that have been bubbling just below the surface, this aspect could provide some powerful insights into the way you operate or even your place in the bigger picture. So be sure to jot down any flashes of inspiration that you receive in this moment; this could be a brilliant chance for you to reconnect with your true purpose.
Here is your horoscope for the week of Monday, June 2, 2025.
Aries
Two heads are often better than one, Aries. And at the beginning of this week, you may find yourself feeling particularly collaborative, making it a great time to feed off the energy of others. Discussing your passions can be a wonderful way to connect during this time; watch how these conversations activate your creativity and help you discover stimulating new hobbies to pursue. Then, your relationship with the physical realm could start to deepen as Venus moves into Taurus later in the week. Use this energy to take stock of how you create — and sustain — security and comfort, and consider whether there are any changes you'd like to make.
Taurus
How are you investing in your future, Taurus? At the start of the week, asking yourself this question may help you identify some actionable steps you can take to gain better control over your finances. You might also find it useful to discuss your desire for stability with those you trust; family members in particular could surprise you with kernels of wisdom and motivate you to really focus on elevating your foundations. Later in the week, your charisma will be magnified as love-ruling Venus enters your sign, and this could give you a bit of a magic touch at work. People will be eager to join your cause as you project true confidence.
Gemini
Have you been shying away from the spotlight lately, Gemini? Spending some quality time with friends may encourage you to come out of your shell and shine at the start of this week. You might even notice that being surrounded by your social circle motivates you to fill up your summer calendar with all kinds of events and get-togethers. On the romance front, single Geminis could find that all this social activity helps to expand their dating pool and leads them straight to a perfect match. Don't be afraid to explore your new connection behind closed doors and get to know one another away from prying eyes.
Cancer
A little reflection can do you a world of good, Cancer. So at the start of this week, make an effort to slow down and really think about where you've been directing your energy as of late. If you have trouble cutting through the background noise, practising meditation could be a great way to quiet your mind. Doing an inventory of your routines might also help you identify ways of saving time so that you can spend more of it with your loved ones. Later in the week, you may feel inclined to focus on cultivating your public-facing relationships. See how your sweet spirit shines in social situations and take advantage of this moment to step outside your comfort zone.
Leo
Fire up the group chat, Leo. Your social circle has the potential to provide you with a wealth of powerful insights at the start of this week, so if you've been feeling stuck creatively or are trying to get an idea off the ground, don't hesitate to tap them for a brainstorming session. Chatting with your favourite people is sure to get your juices flowing and help you refine any pitches you've been working on. You may even discover that one of your nearest and dearest has been waiting for the right moment to share their gifts and start collaborating with you. If you believe in your ideas, this is a beautiful moment to make a meaningful investment.
Virgo
Got ambitious plans for the future, Virgo? You'll likely need to tap into your analytical mind if you want to bring them to life. So at the beginning of this week, take a second to explore and compare the financial strategies that might propel you into a new stratosphere of success. Just be sure to discuss all your options with loved ones before you make any big moves, as their feedback could prove crucial in the long term. Later in the week, you may hear adventure calling and feel driven to fill your schedule with new cultural experiences. Watch how mixing up your usual routine can enrich your life with a renewed sense of purpose.
Libra
Your relationships can help you discover some powerful truths, Libra. So if you find yourself searching for deeper meaning in the world around you, you'll be wise to pay attention to the conversations that arise at the beginning of the week. Your social interactions may become more philosophical during this period, prompting you to spend time discussing the challenges we face as a collective. Let your upbeat and compassionate attitude shine so that you can be a beacon of hope for your friends. Later in the week, you may notice that your sensitivity toward the needs of others heightens even further. Don't be afraid to show people your true intensity.
Scorpio
Your hard work is paying off, Scorpio. And at the start of this week, people may be especially eager to recognize — and reward — your efforts, making this an excellent time to bring attention to the goals you still wish to achieve. Remember that the squeaky wheel usually gets the grease, and talking about your dreams can help convince others to support you in your mission. Then, as Venus changes signs, you may feel driven to nurture your closest relationships. Single Scorpios might also find this energy makes them wary of the superficial and more interested in pursuing just one romantic interest. Show off your softer side and see what happens.
Sagittarius
Take note of the various relationships that are taking shape in your life, Sagittarius. If you're single, the start of this week could offer you the perfect chance to begin a blissful new romance that fits seamlessly into your existing routines. Be ready to take a chance on love. Meanwhile, attached archers may find that this influence makes them more playful and infuses their bond with a renewed sense of excitement. Have fun exploring different pleasures and creating new memories together. Not interested in love right now? An intriguing idea could propel you down a fresh professional path — don't hesitate to team up with someone who understands your vision.
Capricorn
Have you been pouring all of your attention into work lately, Capricorn? It's possible that you've become so focused that you've started to lose sight of what you were initially trying to accomplish. So at the beginning of this week, press pause so you can evaluate where you've really been spending your energy. Perhaps you'll find that it's time to make a course correction so that you can get back in touch with your true purpose. Then, as Venus changes signs later this week, you may feel driven to reconnect with your inner artist. Use the next month of this transit to make things that bring you happiness, and see what turns up along the way.
Aquarius
Go ahead and let your mind wander, Aquarius. If you allow yourself to think outside the box at the start of this week, you could come up with some unconventional — yet brilliant — ideas for improving your surroundings. Perhaps you'll even find that gathering inspiration and making small changes to your space allows you to relax and unwind on a deeper level. Later in the week, as Venus changes signs, you may feel inclined to spend even more time at home. Think of the next month of this transit as a bit of a staycation; it's a wonderful chance to chip away at your domestic to-do list and challenge yourself to live fully in the moment.
Pisces
No one likes feeling rushed, Pisces. So at the beginning of this week, remember to practise patience with yourself and the people around you, especially if you're in the process of creating something new. If you've been working with others, take a moment to really reflect on what you want to say before voicing your impatience or dissatisfaction. It's possible that your realities simply aren't syncing up — try to get on the same page before you lash out. You may also find it useful to reach out to your loved ones during this period. Start talking about the resources you need to manifest your vision; your friends and family will be eager to help you connect the dots.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time11 minutes ago

  • Globe and Mail

Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, 'Multiple sclerosis Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Sclerosis Treatment Landscape. Click here to read more @ Multiple Sclerosis Pipeline Outlook Key Takeaways from the Multiple Sclerosis Pipeline Report In May 2025, Novartis Pharmaceuticals announced a Phase IV study in which breastfeeding mothers treated with ofatumumab and their babies are taking part for up to 1 year. The study consists of a Core Part and a Safety Follow-up Part. The Core Part includes a Screening period and a Sampling period. During the Screening period (up to 4 weeks), the study doctor will assess if mothers can join the study. The Sampling period, during which milk samples and a blood sample will be collected, will last for up to 12 weeks. The Safety Follow-up Part will last for about 9 months, to follow up on health and safety of mothers and their babies. In May 2025, Hoffmann-La Roche announced a study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab. In May 2025, Eli Lilly and Company conducted a study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. In May 2025, Biocad announced a clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies. In May 2025, Sanofi conducted a study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. In May 2025, Biogen organized a study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS. DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment. The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Stay informed about the cutting-edge advancements in Multiple Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Multiple Sclerosis Clinical Trials Assessment Multiple sclerosis Emerging Drugs Profile IMU-838: Immunic Therapeutics Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties. BIIB091: Biogen BIIB091 selectively inhibits Burton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis. IMCY-0141: ImCyse IMCY-0141 is the Company's second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis. NeuroVax: Immune Response BioPharma NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin. NeuroVax is a Once a Month Dosing injection, safe, tolerable, enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a first in class disease modifying Multiple Sclerosis Vaccine. NeuroVax IR has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in it correspond to one or more TCR gene families which are over expressed in 90% of MS patients. The Multiple Sclerosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment. Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different Multiple Sclerosis mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market Learn more about Multiple Sclerosis Drugs opportunities in our groundbreaking Multiple Sclerosis research and development projects @ Multiple Sclerosis Unmet Needs Multiple Sclerosis Companies Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Multiple Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Multiple Sclerosis Pipeline Report Coverage- Global Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Multiple Sclerosis Pipeline on our website @ Multiple Sclerosis Emerging Drugs and Companies Table of Content Introduction Executive Summary Multiple sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Multiple sclerosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) BIIB091: Biogen Drug profiles in the detailed report….. Early Stage Products (Phase I) NeuroVax: Immune Response BioPharma Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Multiple sclerosis Key Companies Multiple sclerosis Key Products Multiple sclerosis- Unmet Needs Multiple sclerosis- Market Drivers and Barriers Multiple sclerosis- Future Perspectives and Conclusion Multiple sclerosis Analyst Views Multiple sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Rock band Heart offering reward for instruments stolen ahead of U.S. tour
Rock band Heart offering reward for instruments stolen ahead of U.S. tour

CBC

time40 minutes ago

  • CBC

Rock band Heart offering reward for instruments stolen ahead of U.S. tour

Two irreplaceable instruments owned by members of the rock band Heart were stolen from a venue in New Jersey last weekend, and the musicians are now offering a reward for information leading to their return. The band was set to kick off its U.S. tour, titled An Evening With Heart, at the Hard Rock Hotel & Casino in Atlantic City, N.J. on Saturday, and its gear had been set up the day prior to the show. Among the items stolen were a custom-built, purple sparkle baritone Telecaster guitar with a hand-painted headstock made for Nancy Wilson, and a vintage 1966 Gibson EM-50 mandolin that Paul Moak has played for over 25 years. "These instruments are more than just tools of our trade — they're extensions of our musical souls," Wilson said in a statement issued by the group. "We're heartbroken, and we're asking for their safe return — no questions asked. Their value to us is immeasurable." Heart is led by Wilson and her sister, Ann, who have made music together since the '70s and have released hits including Barracuda, Magic Man, Crazy on You and Alone. The Rock & Roll Hall of Famers were honoured with a Lifetime Achievement Award from the Recording Academy in 2023. WATCH | Heart performs Crazy on You on the Midnight Special in 1977:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store